Chronic Hepatitis News

Among patients with hepatitis-induced cirrhosis, heavy alcohol consumption increased liver function impairment and hepatocellular carcinoma prevalence, according to research.

Screening for hepatocellular carcinoma is critical in high-risk patients, according to a presentation at GUILD conference 2022.

Novel hepatitis B virus RNA and HBV core-related antigen blood assays revealed continued disease activity despite apparently suppressed virus replication among patients dosed with antiviral therapy for HBV and HIV coinfection.

The CDC’s Advisory Committee on Immunization Practices recently issued a universal recommendation that all adults aged 19 to 59 years receive the hepatitis B vaccine.

Hepatitis D, in hepatitis B surface antigen-positive individuals, may remain undiagnosed due to lack of testing, particularly in primary care settings, according to a poster.

In this video, Nancy S. Reau, MD, FAASLD, AGAF, discussed one of the themes from The Liver Meeting Digital Experience: the effect of the COVID-19 pandemic on hepatitis C care.

In patients with hepatitis C infection who failed treatment with Vosevi, retreatment with a regimen of Sovaldi plus Mavyret plus ribavirin for 16 to 24 weeks was safe and effective, researchers reported.

VBI Vaccines announced that the FDA has approved the company’s recombinant trivalent hepatitis B vaccine, PreHevbrio, for adults aged 18 years or older.

Healio Gastroenterology and Hepatology presents the following report on highlights from The Liver Meeting Digital Experience.

Tenofovir alafenamide therapy was safe, well-tolerated and prevented the transmission of hepatitis B virus from pregnant mothers to infants, according to research presented at The Liver Meeting Digital Experience.